Possible side effects of using corvalizumab and countermeasures

Crovalimab is an inhibitor that targets complement protein C5. It is mainly used to treat paroxysmal nocturnal hemoglobinuria (PNH) in patients 13 years old and above and weighing at least 40kg. PNHIt is a rare and serious blood disease. Patients suffer from anemia, thrombosis and other symptoms due to excessive hemolysis of red blood cells. Kovalizumab inhibits the activity of C5 complement protein and prevents the complement system from attacking red blood cells, thereby alleviating disease symptoms.

However, like other drugs, kovalizumab may cause some side effects during use. These side effects include, but are not limited to, infusion-related reactions, viral infections, respiratory infections (including lung infections), and type III allergic reactions, which manifest as cold symptoms such as pain or swelling in the nose or throat.

Facing these possible side effects, patients and doctors need to take some measures. First of all, during the infusion process, if any discomfort occurs, such as chills, fever, rash and other infusion-related reactions, medical staff should be notified immediately so that the infusion speed can be adjusted or the infusion can be stopped in a timely manner. For viral infections and respiratory infections, patients should maintain good personal hygiene habits, avoid contact with infected people, and use antiviral drugs or antibiotics for treatment under the guidance of a doctor.

For III type allergic reactions, such as the occurrence of cold symptoms, patients should inform their doctors in time for anti-allergic treatment. In addition, patients should closely monitor their condition while taking kovalizumab, and seek medical attention in time if there are any abnormalities.

Patients also need to pay attention to some matters when using kovalizumab. For example, meningococcal vaccination must be completed at least 2 weeks before the first dose and a good immune status must be maintained during the treatment. At the same time, patients should inform doctors of all their medical conditions, including whether they are infected, pregnant, breastfeeding, and other medications they are taking, so that doctors can make reasonable treatment decisions.

In short, although kovarizumab has shown good efficacy in the treatment ofPNH, patients still need to be alert to possible side effects during use and take appropriate countermeasures under the guidance of a doctor to ensure the safety and effectiveness of the treatment.

Reference link: https://www.accessdata.fda.gov/drugsatfda docs/label/2024/761388s000lbl.pdf